Allergy Immunotherapy companies

Key Allergy Immunotherapy Market Players:

The competitive landscape of the allergy immunotherapy industry is inspiring the global players to expand their market share. Companies involved in the emerging markets of the U.S., such as Thermo Fisher Scientific and Regeneron Pharmaceuticals, are leveraging advanced injectable treatments. While other key players, including ALK-Abelló and Stallergenes Greer, are dominating the industry with sublingual and subcutaneous treatments. This is further dragging the interest in conducting research activities and bringing innovation in the field, especially for biologics and immunotherapies targeting severe allergic reactions.

Below is the list of some prominent players operating in the global market:

Company Name	Origin	Market Share (2025)	Industry Focus
ALK-Abelló	Denmark	22.5%	Pure-play allergy leader. Offers SCIT and SLIT products for respiratory allergies and venom immunotherapy.
Stallergenes Greer	UK/U.S.	18.3%	Pure-play allergy leader. Focuses on SCIT and SLIT immunotherapy for a wide range of allergens.
Merck KGaA	Germany	12.8%	Diversified Pharma. Markets the widely prescribed SLIT tablet RAGWITEK in North America.
Aimmune Therapeutics	U.S.	8.2%	Biopharma. Developed PALFORZIA, the first FDA-approved treatment for peanut allergy.
HAL Allergy Group	Netherlands	7.7%	Specialized biopharmaceutical company focused on developing and producing AIT products for Europe.
Biomay AG	Austria	xx%	Biotech company focused on developing innovative, recombinant allergen-based vaccines.
DBV Technologies	France	xx%	Biopharma. Pioneering epicutaneous immunotherapy (EPIT) with its Viaskin™ platform.
Allergy Therapeutics	UK	xx%	Specialist pharmaceutical company developing SCIT and SLIT products with novel technologies.
Leti Pharma	Spain	xx%	Pharmaceutical company specializing in the production of allergen extracts for diagnosis and AIT.
WOLW Pharma	Germany	xx%	Pharmaceutical company focused on the production of allergen extracts for specific immunotherapy (SCIT).
Abbott Laboratories	U.S.	xx%	Diversified Healthcare. Provides a range of allergen extracts for diagnosis and immunotherapy.
Novartis AG	Switzerland	xx%	Diversified Pharma. Markets XOLAIR (omalizumab), used in combination with AIT.
GlaxoSmithKline plc	UK	xx%	Diversified Pharma. Engages in research for novel adjuvant systems for AIT.
Johnson & Johnson	U.S.	xx%	Diversified Healthcare. Engages in immunology R&D with interest in novel allergy treatments.
Sanofi	France	xx%	Diversified Pharma. Has strategic investments in immunology and allergy research.
Torii Pharmaceutical Co., Ltd.	Japan	xx%	Licenses and markets major AIT products in Japan, including SLIT tablets.
Shionogi & Co., Ltd.	Japan	xx%	Diversified Pharma engaged in the development and marketing of allergy treatments.
Mitsubishi Tanabe Pharma	Japan	xx%	Diversified Pharma that develops and markets products for allergic diseases.
ALK-Abelló Japan K.K.	Japan	xx%	The Japanese subsidiary of ALK-Abelló, marketing its global portfolio.
Nippon Zenyaku Kogyo	Japan	xx%	Pharmaceutical company that manufactures drugs, including allergen extracts.

Below are the areas covered for each company in the market:

• Company Overview 
• Business Strategy 
• Key Product Offerings 
• Financial Performance 
• Key Performance Indicators 
• Risk Analysis 
• Recent Development 
• Regional Presence 
• SWOT Analysis